Retatrutide

Also known as: LY3437943, Triple GIP/GLP-1/Glucagon Agonist

Metabolic

Phase III

Retatrutide is a next-generation triple agonist peptide that simultaneously activates GIP (glucose-dependent insulinotropic polypeptide), GLP-1, and glucagon receptors. In Phase 2 trials it produced the largest weight loss ever seen in a pharmacological obesity trial — averaging 24% body weight reduction at 48 weeks.

Regulatory & Approval Status

Not FDA Approved

Retatrutide is an investigational triple agonist currently undergoing Phase 3 clinical trials for obesity and metabolic conditions; it has not received FDA approval.

Information compiled from FDA compounding guidance and public regulatory sources. For research and educational purposes only; not medical advice.

Unlock the complete research profile

Create your free CertifiedTide account to access full compound details, mechanisms, safety data, and research tools.